Eisai Co. Ltd. and Eli Lilly and Co. on April 8 said they still plan to seek accelerated U.S. approval for experimental Alzheimer’s drugs even after the Medicare health plan decided to severely limit coverage of medicines approved in that manner.

Patient groups mounted a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television and local advertisements that began running during the March 13 morning political shows.

President Joe Biden called for the U.S. Senate to approve his Build Back Better legislation to reduce the costs of prescription drugs provided through Medicare and cap out-of-pocket drug costs for seniors.

U.S. President Joe Biden on February 10 said he expected inflation to start to ease during 2022 as supply chain logjams clear up, while saying his administration was already helping ease shortages, as new data showed the biggest jump in consumer prices in 40 years.

Biogen Inc. is urging Medicare to broadly reimburse the company’s recently authorized Alzheimer’s drug, in response to a proposal by the U.S. government to sharply limit coverage of new drugs for the brain-wasting disease.

Alzheimer’s patient groups, disappointed by Medicare’s plan to sharply limit coverage of new drugs for the brain-wasting disease, are planning publicity and lobbying campaigns to protest a proposal they say could delay their use for 10 years.

Biogen shares fell on January 12 after the Centers for Medicare and Medicaid Services (CMS) issued its draft national coverage decision for the company’s controversial Alzheimer’s drug Aduhelm.

The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.

Biogen Inc. is providing the company’s controversial and expensive new Alzheimer’s drug free of charge for some patients amid slow claim reviews by Medicare, according to sources familiar with the situation, including a doctor treating patients with the drug.

pharmaceuticals

President Joe Biden on Aug. 12 called on U.S. lawmakers to enact legislation aimed at lowering drug prices, including allowing Medicare to negotiate drug prices and imposing penalties on drugmakers that hike prices faster than inflation.